![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ALG13 |
Gene summary for ALG13 |
![]() |
Gene information | Species | Human | Gene symbol | ALG13 | Gene ID | 79868 |
Gene name | ALG13 UDP-N-acetylglucosaminyltransferase subunit | |
Gene Alias | CDG1S | |
Cytomap | Xq23 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q9NP73 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79868 | ALG13 | P17T-E | Human | Esophagus | ESCC | 4.70e-06 | 2.57e-01 | 0.1278 |
79868 | ALG13 | P19T-E | Human | Esophagus | ESCC | 9.19e-11 | 4.26e-01 | 0.1662 |
79868 | ALG13 | P20T-E | Human | Esophagus | ESCC | 5.67e-22 | 5.42e-01 | 0.1124 |
79868 | ALG13 | P21T-E | Human | Esophagus | ESCC | 3.12e-17 | 2.82e-01 | 0.1617 |
79868 | ALG13 | P22T-E | Human | Esophagus | ESCC | 6.37e-28 | 5.63e-01 | 0.1236 |
79868 | ALG13 | P23T-E | Human | Esophagus | ESCC | 7.38e-37 | 9.20e-01 | 0.108 |
79868 | ALG13 | P24T-E | Human | Esophagus | ESCC | 4.32e-07 | 2.85e-01 | 0.1287 |
79868 | ALG13 | P26T-E | Human | Esophagus | ESCC | 6.87e-48 | 9.30e-01 | 0.1276 |
79868 | ALG13 | P27T-E | Human | Esophagus | ESCC | 4.09e-17 | 2.65e-01 | 0.1055 |
79868 | ALG13 | P28T-E | Human | Esophagus | ESCC | 1.69e-19 | 4.72e-01 | 0.1149 |
79868 | ALG13 | P30T-E | Human | Esophagus | ESCC | 1.48e-14 | 6.98e-01 | 0.137 |
79868 | ALG13 | P31T-E | Human | Esophagus | ESCC | 1.51e-19 | 3.13e-01 | 0.1251 |
79868 | ALG13 | P32T-E | Human | Esophagus | ESCC | 1.54e-27 | 6.43e-01 | 0.1666 |
79868 | ALG13 | P36T-E | Human | Esophagus | ESCC | 5.82e-22 | 4.39e-01 | 0.1187 |
79868 | ALG13 | P37T-E | Human | Esophagus | ESCC | 3.32e-25 | 5.47e-01 | 0.1371 |
79868 | ALG13 | P38T-E | Human | Esophagus | ESCC | 3.80e-07 | 3.37e-01 | 0.127 |
79868 | ALG13 | P39T-E | Human | Esophagus | ESCC | 9.23e-25 | 5.65e-01 | 0.0894 |
79868 | ALG13 | P40T-E | Human | Esophagus | ESCC | 1.81e-15 | 2.52e-01 | 0.109 |
79868 | ALG13 | P42T-E | Human | Esophagus | ESCC | 1.49e-14 | 3.26e-01 | 0.1175 |
79868 | ALG13 | P44T-E | Human | Esophagus | ESCC | 5.75e-13 | 2.53e-01 | 0.1096 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa005106 | Esophagus | HGIN | N-Glycan biosynthesis | 17/1383 | 53/8465 | 3.43e-03 | 2.54e-02 | 2.02e-02 | 17 |
hsa0051013 | Esophagus | HGIN | N-Glycan biosynthesis | 17/1383 | 53/8465 | 3.43e-03 | 2.54e-02 | 2.02e-02 | 17 |
hsa0051023 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
hsa005136 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
hsa0051033 | Esophagus | ESCC | N-Glycan biosynthesis | 39/4205 | 53/8465 | 3.26e-04 | 1.15e-03 | 5.89e-04 | 39 |
hsa0051313 | Esophagus | ESCC | Various types of N-glycan biosynthesis | 31/4205 | 42/8465 | 1.23e-03 | 3.78e-03 | 1.93e-03 | 31 |
hsa005104 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
hsa005134 | Liver | Cirrhotic | Various types of N-glycan biosynthesis | 26/2530 | 42/8465 | 1.65e-05 | 1.41e-04 | 8.69e-05 | 26 |
hsa0051011 | Liver | Cirrhotic | N-Glycan biosynthesis | 32/2530 | 53/8465 | 3.82e-06 | 4.10e-05 | 2.53e-05 | 32 |
hsa0051311 | Liver | Cirrhotic | Various types of N-glycan biosynthesis | 26/2530 | 42/8465 | 1.65e-05 | 1.41e-04 | 8.69e-05 | 26 |
hsa0051021 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
hsa005132 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
hsa0051031 | Liver | HCC | N-Glycan biosynthesis | 40/4020 | 53/8465 | 2.95e-05 | 1.87e-04 | 1.04e-04 | 40 |
hsa005133 | Liver | HCC | Various types of N-glycan biosynthesis | 30/4020 | 42/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 30 |
hsa005105 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
hsa005135 | Oral cavity | OSCC | Various types of N-glycan biosynthesis | 29/3704 | 42/8465 | 8.03e-04 | 2.32e-03 | 1.18e-03 | 29 |
hsa0051012 | Oral cavity | OSCC | N-Glycan biosynthesis | 39/3704 | 53/8465 | 9.77e-06 | 4.36e-05 | 2.22e-05 | 39 |
hsa0051312 | Oral cavity | OSCC | Various types of N-glycan biosynthesis | 29/3704 | 42/8465 | 8.03e-04 | 2.32e-03 | 1.18e-03 | 29 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALG13 | SNV | Missense_Mutation | rs771549283 | c.1918N>A | p.Glu640Lys | p.E640K | Q9NP73 | protein_coding | tolerated(0.11) | benign(0.049) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |
ALG13 | SNV | Missense_Mutation | c.2090G>T | p.Arg697Leu | p.R697L | Q9NP73 | protein_coding | deleterious(0.02) | benign(0.114) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD | |
ALG13 | SNV | Missense_Mutation | novel | c.3271G>T | p.Asp1091Tyr | p.D1091Y | Q9NP73 | protein_coding | tolerated(0.06) | possibly_damaging(0.781) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ALG13 | SNV | Missense_Mutation | novel | c.602T>C | p.Leu201Pro | p.L201P | Q9NP73 | protein_coding | tolerated_low_confidence(0.34) | benign(0) | TCGA-AR-A24X-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
ALG13 | SNV | Missense_Mutation | c.3328N>G | p.Gln1110Glu | p.Q1110E | Q9NP73 | protein_coding | deleterious(0.04) | benign(0.026) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
ALG13 | SNV | Missense_Mutation | rs374660036 | c.1781G>A | p.Arg594Gln | p.R594Q | Q9NP73 | protein_coding | deleterious(0) | probably_damaging(0.949) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ALG13 | insertion | Frame_Shift_Ins | novel | c.2417_2418insGGAGGGCAATGGCCAGAGTGAAAATGGTGAGTCAA | p.Ser807GlufsTer50 | p.S807Efs*50 | Q9NP73 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ALG13 | SNV | Missense_Mutation | novel | c.520N>A | p.Leu174Ile | p.L174I | Q9NP73 | protein_coding | tolerated_low_confidence(0.13) | benign(0.001) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ALG13 | SNV | Missense_Mutation | rs138712375 | c.2606C>T | p.Ala869Val | p.A869V | Q9NP73 | protein_coding | tolerated(0.12) | benign(0.022) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ALG13 | SNV | Missense_Mutation | novel | c.2836N>T | p.Ala946Ser | p.A946S | Q9NP73 | protein_coding | tolerated(0.84) | benign(0) | TCGA-C5-A2LT-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |